EICHORCondition: Myasthenia Gravis · Generalized Myasthenia Gravis · Sponsor: Kyverna Therapeutics
A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis
This description comes directly from the study's public registry record.
Kyverna Therapeutics, Inc. · 510-925-2484 · Clinicaltrials@kyvernatx.com
Always discuss trial participation with your own doctor first.
| Ronald Reagan UCLA Medical Center | Los Angeles, California, United States | Recruiting |
| University of California, Irvine | Orange, California, United States | Recruiting |
| Stanford University Medical Center | Palo Alto, California, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Indiana University Health | Indianapolis, Indiana, United States | Recruiting |
| University of Missouri | Columbia, Missouri, United States | Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Recruiting |
| Thomas Jefferson University Hospital | Philadelphia, Pennsylvania, United States | Recruiting |
| Houston Methodist Hospital | Houston, Texas, United States | Recruiting |
| Intermountain Medical Center | Murray, Utah, United States | Recruiting |
| Westmead Institute for Medical Research | Westmead, Australia | Recruiting |
| Hospital Israelita Albert Einstein | São Paulo, Brazil | Recruiting |
+ 10 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06193889